Author:
Pathmanathan Shivanshan,Dzienis Marcin
Abstract
A 52-year-old male patient with hyaluronic acid-based dermal fillers injected in his cheeks was diagnosed with glossotonsillary malignancy, and managed with concurrent cetuximab (epidermal growth factor receptor inhibitor) and radiation therapy. He developed significant inflammation around the dermal filler sites after first cycle of cetuximab which improved with dissolution of the dermal fillers with hyaluronidase. This suggests that cetuximab can lead to inflammation around the dermal filler sites, which can be treated with dissolution of the filler.
Reference9 articles.
1. NCCN guidelines Version 1.2019 - March 6. 2019
https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
2. NCCN guidelines Version 2.2019 - May 15. 2019
https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
3. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy;Pinto;Oncologist,2011
4. EGFR regulation of epidermal barrier function;Tran;Physiol Genomics,2012
5. Acneiform rash induced by EGFR inhibitors: review of the literature and new insights;Fabbrocini;Skin Appendage Disord,2015
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献